ATE461217T1 - Glp-1-verbindungen - Google Patents

Glp-1-verbindungen

Info

Publication number: ATE461217T1
Authority: AT; Austria
Prior art keywords: compounds; glp; therapeutic use; novel glp; novel
Prior art date: 2003-12-18

Application number

AT04803037T

Other languages

English (en)

Inventor

Nils Langeland Johansen

Jesper Lau

Kjeld Madsen

Thomas Kruse Hansen

Jeppe Sturis

Original Assignee

Novo Nordisk As

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2003-12-18

Filing date

2004-12-17

Publication date

2010-04-15

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34702152&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE461217(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2004-12-17 Application filed by Novo Nordisk As filed Critical Novo Nordisk As

2010-04-15 Application granted granted Critical

2010-04-15 Publication of ATE461217T1 publication Critical patent/ATE461217T1/de

Links

DTHNMHAUYICORS-KTKZVXAJSA-N Glucagon-like peptide 1 Chemical class C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 DTHNMHAUYICORS-KTKZVXAJSA-N 0.000 title abstract 2
230000001225 therapeutic effect Effects 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/57563—Vasoactive intestinal peptide [VIP]; Related peptides
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/605—Glucagons
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Public Health (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Endocrinology (AREA)
Diabetes (AREA)
Biochemistry (AREA)
Molecular Biology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Genetics & Genomics (AREA)
Biophysics (AREA)
Gastroenterology & Hepatology (AREA)
Zoology (AREA)
Toxicology (AREA)
Obesity (AREA)
Hematology (AREA)
Vascular Medicine (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Psychiatry (AREA)
Urology & Nephrology (AREA)
Child & Adolescent Psychology (AREA)
Emergency Medicine (AREA)
Hospice & Palliative Care (AREA)
Nutrition Science (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

AT04803037T 2003-12-18 2004-12-17 Glp-1-verbindungen ATE461217T1 (de)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
DKPA200301885		2003-12-18
DKPA200401090		2004-07-09
PCT/DK2004/000886 WO2005058954A1 (en)	2003-12-18	2004-12-17	Novel glp-1 compounds

Publications (1)

Publication Number	Publication Date
ATE461217T1 true ATE461217T1 (de)	2010-04-15

Family

ID=34702152

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT04803037T ATE461217T1 (de)	2003-12-18	2004-12-17	Glp-1-verbindungen

Country Status (12)

Country	Link
US (2)	US20070042956A1 (de)
EP (1)	EP1704165B1 (de)
JP (1)	JP2007537141A (de)
KR (1)	KR20060135661A (de)
AT (1)	ATE461217T1 (de)
AU (1)	AU2004298424A1 (de)
BR (1)	BRPI0417717A (de)
CA (1)	CA2549582A1 (de)
DE (1)	DE602004026113D1 (de)
MX (1)	MXPA06006745A (de)
RU (1)	RU2006120079A (de)
WO (1)	WO2005058954A1 (de)

Families Citing this family (88)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP1605897B1 (de)	2003-03-19	2012-07-25	Eli Lilly And Company	Polyethelen-glycol-link-glp-1-verbindungen
MXPA06006745A (es)	2003-12-18	2006-08-18	Novo Nordisk As	Compuestos glp-1 novedosos.
TWI376234B (en)	2005-02-01	2012-11-11	Msd Oss Bv	Conjugates of a polypeptide and an oligosaccharide
BRPI0607775A2 (en) *	2005-02-16	2018-06-26	Novo Nordisk A/S	conjugate, pharmaceutical composition, use of a compound, and method for treating or preventing disease
TWI372629B (en)	2005-03-18	2012-09-21	Novo Nordisk As	Acylated glp-1 compounds
JP5755398B2 (ja)	2005-03-18	2015-07-29	ノヴォノルディスクアー／エス	伸長されたｇｌｐ−１化合物
US8759290B2 (en) *	2005-10-18	2014-06-24	Biocon Limited	Oral glucagon-like peptide conjugates for metabolic diseases
BRPI0617740A2 (pt)	2005-10-26	2011-08-02	Lilly Co Eli	agonistas seletivos peptìdicos do receptor vpac2, composição farmacêutica e uso dos referidos agonistas
EP2570133B1 (de)	2005-11-07	2016-03-23	Indiana University Research and Technology Corporation	Glucagonanaloga mit physiologischer Löslichkeit und Stabilität
JP5096363B2 (ja)	2005-12-16	2012-12-12	ネクターセラピューティックス	Ｇｌｐ−１のポリマ複合体
ES2495741T3 (es) *	2006-04-20	2014-09-17	Amgen, Inc	Compuestos de GLP-1
FR2904627B1 (fr) *	2006-08-04	2008-11-07	Pasteur Institut	Nouveaux peptides actives, purifies et isoles, derives du recepteur cd4 (mini-cd4) et leur procece de preparation
CN101125207B (zh) *	2006-11-14	2012-09-05	上海华谊生物技术有限公司	带有聚乙二醇基团的艾塞丁或其类似物及其制剂和用途
RU2477286C2 (ru) *	2007-01-05	2013-03-10	Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн	АНАЛОГИ ГЛЮКАГОНА, ОБЛАДАЮЩИЕ ПОВЫШЕННОЙ РАСТВОРИМОСТЬЮ В БУФЕРАХ С ФИЗИОЛОГИЧЕСКИМ ЗНАЧЕНИЕМ pH
AU2008216265B2 (en)	2007-02-15	2014-04-03	Indiana University Research And Technology Corporation	Glucagon/GLP-1 receptor co-agonists
WO2009030774A1 (en)	2007-09-05	2009-03-12	Novo Nordisk A/S	Truncated glp-1 derivatives and their therapeutical use
EP2190872B1 (de) *	2007-09-05	2018-03-14	Novo Nordisk A/S	Glucagon-like peptid-1-derivate und ihre pharmazeutische verwendung
US20100261637A1 (en)	2007-09-05	2010-10-14	Novo Nordisk A/S	Peptides derivatized with a-b-c-d- and their therapeutical use
US20100256056A1 (en) *	2007-09-07	2010-10-07	Zheng Xin Dong	Analogues of exendin-4 and exendin-3
GB0717399D0 (en) *	2007-09-07	2007-10-17	Uutech Ltd	Use of GLP-1 analogues for the treatment of disorders associated with dysfunctional synaptic transmission
US8980830B2 (en) *	2007-10-30	2015-03-17	Indiana University Research And Technology Corporation	Peptide compounds exhibiting glucagon antagonist and GLP-1 agonist activity
WO2009058662A2 (en) *	2007-10-30	2009-05-07	Indiana University Research And Technology Corporation	Glucagon antagonists
AU2009210570B2 (en) *	2008-01-30	2014-11-20	Indiana University Research And Technology Corporation	Ester-based insulin prodrugs
EP2087911A1 (de)	2008-02-06	2009-08-12	Institut Pasteur	Konjugierte Moleküle mit einem Peptid aus dem mit einem Polyanion gekoppelten CD4-Rezeptor zur Behandlung von AIDS
WO2009152289A1 (en) *	2008-06-11	2009-12-17	Indiana University Research And Technology Corporation	Methods for enhancing adsorption of molecules
EP2300037B1 (de)	2008-06-17	2016-03-30	Indiana University Research and Technology Corporation	Coagonisten des glucagon/glp-1 rezeptors
WO2009155257A1 (en) *	2008-06-17	2009-12-23	Indiana University Research And Technology Corporation	Glucagon analogs exhibiting enhanced solubility and stability physiological ph buffers
DK2300035T3 (en) *	2008-06-17	2015-11-16	Univ Indiana Res & Tech Corp	Mixed GIP-based agonists for the treatment of metabolic diseases and obesity
KR20110039348A (ko)	2008-08-06	2011-04-15	노보 노르디스크 헬스 케어 악티엔게젤샤프트	연장된 생체내 효능을 가지는 콘쥬게이트된 단백질
TW201012829A (en) *	2008-09-22	2010-04-01	Ipsen Mfg Ireland Ltd	Process for the synthesis of (Aib8,35)hGLP-1(7-36)-NH2
CN102325539A (zh)	2008-12-19	2012-01-18	印第安纳大学研究及科技有限公司	基于酰胺的胰高血糖素超家族肽前药
JP5816097B2 (ja)	2009-01-22	2015-11-18	ノヴォ・ノルディスク・ヘルス・ケア・アーゲー	安定な成長ホルモン化合物
WO2010148089A1 (en)	2009-06-16	2010-12-23	Indiana University Research And Technology Corporation	Gip receptor-active glucagon compounds
JP6086528B2 (ja)	2009-08-06	2017-03-01	ノヴォ・ノルディスク・ヘルス・ケア・アーゲー	長期のインビボ有効性を有する成長ホルモン
EP2512518A1 (de)	2009-12-16	2012-10-24	Novo Nordisk A/S	Glp-1-rezeptoragonistverbindungen mit modifiziertem n-terminus
US8703701B2 (en)	2009-12-18	2014-04-22	Indiana University Research And Technology Corporation	Glucagon/GLP-1 receptor co-agonists
CN118767117A (zh)	2010-01-22	2024-10-15	诺沃—诺迪斯克保健股份有限公司	体内功效延长的生长激素
JP5980689B2 (ja)	2010-01-22	2016-08-31	ノヴォ・ノルディスク・ヘルス・ケア・アーゲー	安定な成長ホルモン化合物
EP2528618A4 (de)	2010-01-27	2015-05-27	Univ Indiana Res & Tech Corp	Glucagon-antagonisten- und gip-agonisten-konjugate sowie zusammensetzungen zur behandlung von stoffwechselerkrankungen und adipositas
CA2797095A1 (en)	2010-05-13	2011-11-17	Indiana University Research And Technology Corporation	Glucagon superfamily peptides exhibiting nuclear hormone receptor activity
WO2011143208A1 (en)	2010-05-13	2011-11-17	Indiana University Research And Technology Corporation	Glucagon superfamily peptides exhibiting g protein-coupled receptor activity
RU2580317C2 (ru)	2010-06-24	2016-04-10	Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн	Пептидные пролекарства, принадлежащие к суперсемейству амид-содержащих глюкагонов
MX377589B (es)	2010-12-16	2025-03-10	Novo Nordisk As	Composiciones sólidas que comprenden agonista de glp-1 y sal del ácido n-(8-(2-hidroxibenzoil)amino)caprílico.
US8507428B2 (en)	2010-12-22	2013-08-13	Indiana University Research And Technology Corporation	Glucagon analogs exhibiting GIP receptor activity
RU2602601C2 (ru)	2011-04-12	2016-11-20	Ново Нордиск А/С	Дважды ацилированные производные glp-1
RS56173B1 (sr)	2011-06-22	2017-11-30	Univ Indiana Res & Tech Corp	Koagonisti receptora za glukagon/glp-1 receptora
BR112013032717A2 (pt)	2011-06-22	2017-01-24	Univ Indiana Res & Tech Corp	coagonistas do receptor de glucagon/glp-1
RU2014117678A (ru)	2011-11-17	2015-12-27	Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн	Пептиды глюкагонового суперсемейства, обладающие глюкокортикоидной рецепторной активностью
EP3542790B1 (de)	2012-03-22	2023-09-13	Novo Nordisk A/S	Zusammensetzungen mit einem abgabemittel und herstellung davon
DK2827845T3 (en)	2012-03-22	2019-04-01	Novo Nordisk As	COMPOSITIONS INCLUDING A PROCEDURE AND PREPARING THEREOF
CN104203266B (zh)	2012-03-22	2017-12-26	诺和诺德股份有限公司	Glp‑1肽组合物及其制备
ES2629735T3 (es)	2012-05-08	2017-08-14	Novo Nordisk A/S	Derivados de GLP-1 doblemente acilados
JP6250034B2 (ja) *	2012-05-08	2017-12-20	ノヴォノルディスクアー／エス	二重アシル化されたｇｌｐ−１誘導体
JP6517690B2 (ja)	2012-06-20	2019-05-22	ノヴォノルディスクアー／エス	ペプチド及び送達剤を含む錠剤製剤
CA2877358A1 (en)	2012-06-21	2013-12-27	Indiana University Research And Technology Corporation	Glucagon analogs exhibiting gip receptor activity
US20150273069A1 (en)	2012-10-17	2015-10-01	Novo Nordisk A/S	Fatty acid acylated amino acids for oral peptide delivery
WO2014158900A1 (en)	2013-03-14	2014-10-02	Indiana University Research And Technology Corporation	Insulin-incretin conjugates
US11045523B2 (en)	2013-04-05	2021-06-29	Novo Nordisk Healthcare Ag	Formulation of growth hormone albumin-binder conjugate
JP6672140B2 (ja)	2013-05-02	2020-03-25	ノヴォノルディスクアー／エス	Ｇｌｐ−１化合物の経口投薬
CN112043835B (zh)	2013-12-06	2022-10-21	韩捷	用于含氮和羟基的药物的生物可逆引入基团
ES2822994T3 (es)	2014-09-24	2021-05-05	Univ Indiana Res & Tech Corp	Conjugados de incretina-insulina
DK3006045T3 (en)	2014-10-07	2017-07-17	Cyprumed Gmbh	Pharmaceutical formulations for oral administration of peptide or protein drugs
EP3359181A1 (de)	2015-10-07	2018-08-15	Cyprumed GmbH	Pharmazeutische formulierungen zur oralen verabreichung von peptidarzneimitteln
WO2018065634A1 (en)	2016-10-07	2018-04-12	Cyprumed Gmbh	Pharmaceutical compositions for the nasal delivery of peptide or protein drugs
HRP20240485T1 (hr)	2017-08-24	2024-07-05	Novo Nordisk A/S	Pripravci glp-1 i njihova upotreba
PL3746111T3 (pl)	2018-02-02	2024-01-15	Novo Nordisk A/S	Stałe kompozycje zawierające agonistę glp-1 i sól kwasu n-(8-(2- hydroksybenzoilo)amino kaprylowego i substancję poślizgową
EP3773475A1 (de)	2018-04-06	2021-02-17	Cyprumed GmbH	Pharmazeutische zusammensetzungen zur transmukosalen abgabe von therapeutischen peptiden und proteinen
TWI829687B (zh)	2018-05-07	2024-01-21	丹麥商諾佛儂迪克股份有限公司	包含glp-1促效劑與n-(8-(2-羥基苯甲醯基)胺基)辛酸之鹽的固體組成物
EP3897570A1 (de)	2018-12-19	2021-10-27	KRKA, d.d., Novo mesto	Pharmazeutische zusammensetzung mit glp-1-analog
WO2021123228A1 (en)	2019-12-18	2021-06-24	Krka, D.D., Novo Mesto	Pharmaceutical composition comprising glp-1 analogue
CN119841865A (zh)	2020-02-07	2025-04-18	加舒布鲁姆生物公司	杂环glp-1激动剂
CN111253475B (zh) *	2020-02-18	2021-03-09	江苏诺泰澳赛诺生物制药股份有限公司	Glp-1激动多肽化合物及其盐与合成方法及用途
EP4142695B1 (de)	2020-04-29	2025-11-05	Novo Nordisk A/S	Feste zusammensetzungen mit einem glp-1-agonisten und histidin
FI4143183T3 (fi)	2020-04-29	2026-01-07	Gasherbrum Bio Inc	Heterosyklisiä glp-1-agonisteja
PE20231181A1 (es)	2020-08-06	2023-08-11	Gasherbrum Bio Inc	Agonistas del glp-1 heterociclicos
WO2022049310A1 (en)	2020-09-07	2022-03-10	Cyprumed Gmbh	Improved pharmaceutical formulations of glp-1 receptor agonists
CN114729060B (zh)	2020-09-30	2022-11-25	北京质肽生物医药科技有限公司	多肽缀合物和使用方法
WO2023012263A1 (en)	2021-08-04	2023-02-09	Novo Nordisk A/S	Solid oral peptide formulations
CN119137124A (zh)	2022-03-09	2024-12-13	加舒布鲁姆生物公司	杂环glp-1激动剂
WO2023179542A1 (en)	2022-03-21	2023-09-28	Gasherbrum Bio , Inc.	5,8-dihydro-1,7-naphthyridine derivatives as glp-1 agonists for the treatment of diabetes
EP4323413A4 (de)	2022-03-30	2025-10-15	Beijing Ql Biopharmaceutical Co Ltd	Flüssige pharmazeutische zusammensetzungen aus polypeptidkonjugaten und verfahren zur verwendung davon
WO2023198140A1 (en)	2022-04-14	2023-10-19	Gasherbrum Bio, Inc.	Heterocyclic glp-1 agonists
JP2026502943A (ja)	2022-12-30	2026-01-27	アルギファルマエーエス	経口投与されるポリペプチド治療剤の全身バイオアベイラビリティを高める組成物および方法
WO2024165571A2 (en)	2023-02-06	2024-08-15	E-Therapeutics Plc	Inhibitors of expression and/or function
WO2025125576A2 (en)	2023-12-15	2025-06-19	E-Therapeutics Plc	Inhibitors of expression and/or function
EP4686757A1 (de)	2024-07-31	2026-02-04	e-therapeutics PLC	Inhibitoren der expression und/oder funktion
WO2025133348A1 (en)	2023-12-22	2025-06-26	E-Therapeutics Plc	Inhibitors of expression and/or function
WO2025196502A1 (en)	2024-03-20	2025-09-25	North Carolina Agricultural & Technical State University	Choline kinase inhibitors as a therapeutic treatment for obesity

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3862167A (en)	1965-08-11	1975-01-21	Mitsui Toatsu Chemicals	Certain 2-acylamine-4-methyl-5-halothiazoles
ATE164852T1 (de)	1990-01-24	1998-04-15	Douglas I Buckley	Glp-1-analoga verwendbar in der diabetesbehandlung
US5545618A (en) *	1990-01-24	1996-08-13	Buckley; Douglas I.	GLP-1 analogs useful for diabetes treatment
US5932462A (en)	1995-01-10	1999-08-03	Shearwater Polymers, Inc.	Multiarmed, monofunctional, polymer for coupling to molecules and surfaces
US5672662A (en)	1995-07-07	1997-09-30	Shearwater Polymers, Inc.	Poly(ethylene glycol) and related polymers monosubstituted with propionic or butanoic acids and functional derivatives thereof for biotechnical applications
IL128332A0 (en)	1996-08-30	2000-01-31	Novo Nordisk As	GLP-1 derivatives
JP2002512175A (ja)	1998-02-27	2002-04-23	ノボノルディスクアクティーゼルスカブ	Ｇｌｐ−１類似体の誘導体類
WO2000012116A1 (en)	1998-08-28	2000-03-09	Eli Lilly And Company	Method for administering insulinotropic peptides
MY155270A (en)	1998-09-24	2015-09-30	Lilly Co Eli	Use of glp-1 or analogs in treatment of stroke
DE69922043T2 (de)	1998-12-07	2005-11-24	Société de Conseils de Recherches et d'Applications Scientifiques S.A.S.	Glp-1 analoge
JP2002544127A (ja) *	1999-04-30	2002-12-24	アミリン・ファーマシューティカルズ，インコーポレイテッド	修飾されたエキセンジンおよびエキセンジン・アゴニスト
US6924264B1 (en) *	1999-04-30	2005-08-02	Amylin Pharmaceuticals, Inc.	Modified exendins and exendin agonists
EP1076066A1 (de)	1999-07-12	2001-02-14	Zealand Pharmaceuticals A/S	Peptide zur Senkung des Blutglukosespiegels
KR100345214B1 (ko) *	1999-08-17	2002-07-25	이강춘	생체적합성 고분자가 수식된 펩타이드의 비점막 전달
WO2001051071A2 (en)	2000-01-11	2001-07-19	Novo Nordisk A/S	Transepithelial delivery of glp-1 derivatives
US6858580B2 (en)	2001-06-04	2005-02-22	Nobex Corporation	Mixtures of drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US6864069B2 (en) *	2001-10-05	2005-03-08	Bayer Pharmaceuticals Corporation	Peptides acting as both GLP-1 receptor agonists and glucagon receptor antagonists and their pharmacological methods of use
AR036711A1 (es) *	2001-10-05	2004-09-29	Bayer Corp	Peptidos que actuan como agonistas del receptor del glp-1 y como antagonistas del receptor del glucagon y sus metodos de uso farmacologico
US20030191056A1 (en) *	2002-04-04	2003-10-09	Kenneth Walker	Use of transthyretin peptide/protein fusions to increase the serum half-life of pharmacologically active peptides/proteins
JP2006501820A (ja) *	2002-09-06	2006-01-19	バイエル・フアーマシユーチカルズ・コーポレーシヨン	修飾ｇｌｐ−１受容体アゴニストおよびそれらの薬理学的使用法
EP1605897B1 (de) *	2003-03-19	2012-07-25	Eli Lilly And Company	Polyethelen-glycol-link-glp-1-verbindungen
SI2107069T1 (sl)	2003-08-05	2013-04-30	Novo Nordisk A/S	Novi inzulinski derivati
AU2004274494A1 (en) *	2003-09-19	2005-03-31	The Scripps Research Institute	Peptide that binds to a broadly neutralizing anti-HIV antibody-structure of 4E10 FAB fragment complex, uses thereof, compositions therefrom
MXPA06006745A (es)	2003-12-18	2006-08-18	Novo Nordisk As	Compuestos glp-1 novedosos.
WO2007017053A1 (en)	2005-07-27	2007-02-15	Novo Nordisk A/S	Syringe device with a dose limiting mechanism and an additional safety mechanism
CN101912648B (zh)	2008-01-23	2013-04-24	诺沃-诺迪斯克有限公司	用于注射所分配剂量的液体药物的设备

2004
- 2004-12-17 MX MXPA06006745A patent/MXPA06006745A/es not_active Application Discontinuation
- 2004-12-17 BR BRPI0417717-7A patent/BRPI0417717A/pt not_active IP Right Cessation
- 2004-12-17 AU AU2004298424A patent/AU2004298424A1/en not_active Abandoned
- 2004-12-17 WO PCT/DK2004/000886 patent/WO2005058954A1/en not_active Ceased
- 2004-12-17 JP JP2006544220A patent/JP2007537141A/ja not_active Withdrawn
- 2004-12-17 EP EP04803037A patent/EP1704165B1/de not_active Revoked
- 2004-12-17 KR KR1020067011699A patent/KR20060135661A/ko not_active Withdrawn
- 2004-12-17 DE DE602004026113T patent/DE602004026113D1/de not_active Expired - Lifetime
- 2004-12-17 AT AT04803037T patent/ATE461217T1/de not_active IP Right Cessation
- 2004-12-17 CA CA002549582A patent/CA2549582A1/en not_active Abandoned
- 2004-12-17 RU RU2006120079/13A patent/RU2006120079A/ru unknown
2006
- 2006-06-16 US US11/454,804 patent/US20070042956A1/en not_active Abandoned
2012
- 2012-05-16 US US13/473,154 patent/US9920106B2/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
DE602004026113D1 (de)	2010-04-29
AU2004298424A1 (en)	2005-06-30
WO2005058954A1 (en)	2005-06-30
RU2006120079A (ru)	2008-01-27
US20120289453A1 (en)	2012-11-15
CA2549582A1 (en)	2005-06-30
BRPI0417717A (pt)	2007-04-03
EP1704165B1 (de)	2010-03-17
JP2007537141A (ja)	2007-12-20
EP1704165A1 (de)	2006-09-27
US9920106B2 (en)	2018-03-20
US20070042956A1 (en)	2007-02-22
KR20060135661A (ko)	2006-12-29
MXPA06006745A (es)	2006-08-18

Legal Events

Date	Code	Title	Description
2010-09-15	RER	Ceased as to paragraph 5 lit. 3 law introducing patent treaties

Publication	Publication Date	Title
ATE461217T1 (de)	2010-04-15	Glp-1-verbindungen
NO20075342L (no)	2007-12-18	Acylerte GLP-1-forbindelser.
NO20044597L (no)	2004-10-27	Kjemiske forbindelser
NO20052914D0 (no)	2005-06-15	Terapeutiske forbindelser
NO20053974D0 (no)	2005-08-25	Tienopyrimidinforbindelser og anvendelse derav.
EP1495141A4 (de)	2006-03-22	Hiv-therapeutikum
SE0301653D0 (sv)	2003-06-05	Novel compounds
DK1572229T3 (da)	2014-06-23	Stabilt terapeutisk fibrinogen
EP1570270A4 (de)	2010-09-22	Therapeutische biokonjugate
SE0301650D0 (sv)	2003-06-04	Novel compounds
DK1597171T3 (da)	2013-02-11	Terapeutisk mikroskum
NL1024677A1 (nl)	2004-05-06	Therapeutische prolinederivaten.
DK1553950T3 (da)	2007-10-15	Terapeutisk behandling
NO20050689L (no)	2005-03-21	Terapeutisk anvendelse
ATE399532T1 (de)	2008-07-15	Medizinische seife
IS7441A (is)	2004-09-08	Peptíðdeformýlasatálmar
NO20022747L (no)	2003-12-08	Behandlingsstol
FI20021817A0 (fi)	2002-10-14	Kanyyli
DE60232650D1 (de)	2009-07-30	Peptiddeformylaseinhibitoren
EP1654537A4 (de)	2007-01-10	Tssk4: eine menschliche testisspezifische serin/threonin-kinase
SE0203826D0 (sv)	2002-12-20	Therapeutic agents
SE0200450D0 (sv)	2002-02-13	Therapeutic agents
SE0201783D0 (sv)	2002-06-11	Medical use
SE0202239D0 (sv)	2002-07-17	Novel use
SE0200410D0 (sv)	2002-02-05	Novel use